TAXUS ATLAS: TAXUS Liberté™-SR Stent for the Treatment of de Novo Coronary Artery Lesions
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00371709 |
Recruitment Status :
Completed
First Posted : September 4, 2006
Last Update Posted : February 2, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Coronary Artery Disease | Device: TAXUS Liberté-SR Device: TAXUS™ Express | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 871 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | TAXUS ATLAS: A Multi-center, Single-arm Study of the TAXUS Liberté™-SR Stent for the Treatment of Patients With de Novo Coronary Artery Lesions |
Study Start Date : | August 2004 |
Actual Primary Completion Date : | November 2005 |
Actual Study Completion Date : | March 2010 |
Arm | Intervention/treatment |
---|---|
Experimental: Arm 1 |
Device: TAXUS Liberté-SR
Paclitaxel-Eluting Coronary Stent System |
Arm 2
Historical Comparator: control data derived from the TAXUS IV and TAXUS V studies
|
Device: TAXUS™ Express
Paclitaxel-Eluting Coronary Stent System |
- 9-Month Target Vessel Revascularization (TVR) [ Time Frame: 9 Months ]
- Clinical procedural and technical success [ Time Frame: 5 Years ]
- Utilization parameters (equipment utilization; catheters, guidewires and balloons, procedure time, fluoroscopic time and amount of contrast used) [ Time Frame: 9 Months ]
- MACE rates at discharge, 1, 4 and 9-months and 1, 2, 3, 4, and 5 years post-index procedure. [ Time Frame: 5 Years ]
- Stent thrombosis rate [ Time Frame: 5 Years ]
- Target Vessel Failure (TVF) [ Time Frame: 5 Years ]
- QCA parameters (binary restenosis rate, MLD and late loss) [ Time Frame: 9 Months ]
- IVUS parameters (percent net volume obstruction, incomplete apposition, stent and area volumes, neointimal area volume) for patients in the IVUS subset [ Time Frame: 9 Months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
General Inclusion Criteria:
- Patient is ≥18 years old.
- Eligible for percutaneous coronary intervention (PCI)
- Documented stable angina pectoris or unstable angina pectoris with documented ischemia or documented silent ischemia
- Left ventricular ejection fraction (LVEF) of >/=25%
- Acceptable candidate for coronary artery bypass grafting (CABG)
- Patient or legal guardian understands the study requirements and the treatment procedures and provides written Informed Consent before any study-specific tests or procedures are performed
- Willing to comply with all specified follow-up evaluations
Angiographic Inclusion Criteria:
- Only one lesion (target lesion) may be treated with the study stent. However, one additional lesion in a non-target vessel may be treated during the index procedure with a commercially available bare metal stent, heparin-coated stent or TAXUS Express stent.
- Target lesion enrolled for treatment may be composed of multiple lesions (not more than 10mm between diseased segments)but must be completely covered by one study stent.
- Target lesion located within a single native coronary artery
- Cumulative target lesion length is ≥10 mm and ≤28 mm (visual estimate)
- RVD of ≥2.5 mm to ≤4.0 mm (visual estimate)
- Target lesion diameter stenosis ≥50% (visual estimate)
- Target lesion is de novo (i.e., a coronary lesion not previously treated)
General Exclusion Criteria:
- Known hypersensitivity to paclitaxel
- Any previous, concurrent or planned treatment with a non-study anti-restenotic drug-coated or drug-eluting coronary stent.
- Previous or planned use of both the study stent and a non-study stent (i.e., commercial stent) in the treatment of the target vessel
- Previous or planned treatment with intravascular brachytherapy in the target vessel
- Planned CABG ≤9-months post-index procedure
- MI within 72 hours prior to the index procedure and or creatine kinase(CK) >2x the local laboratory's ULN unless CK-MB is <2x ULN.
- Cerebrovascular Accident (CVA) within the past 6 months
- Cardiogenic Shock
- Acute or chronic renal dysfunction
- Contraindication to ASA, or to both clopidogrel and ticlopidine
- Leukopenia
- Thrombocytopenia or thrombocytosis
- Active peptic ulcer or active gastrointestinal (GI) bleeding
- Known allergy to stainless steel
- Any prior true anaphylactic reaction to contrast agents
- Patient is currently, or has been treated with paclitaxel or other chemotherapeutic agents within 12-months of the index procedure
- Anticipated treatment with paclitaxel or oral rapamycin during any period in the 9-months after the index procedure
- Male or female with known intention to procreate within 3 months after the index procedure
- Female of childbearing potential with a positive pregnancy test within 7 days before the index procedure, or lactating, or intends to become pregnant during the study.
- Life expectancy of less than 24-months due to other medical condition
- Co-morbid condition(s) that could limit the patient's ability to participate in the study, compliance with follow-up requirements or impact the scientific integrity of the study
- Currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study.
Angiographic Exclusion Criteria:
- Left main coronary artery disease (stenosis >50%) whether protected or unprotected
- Target lesion is ostial in location (within 3.0 mm of vessel origin)
- Target lesion and/or target vessel proximal to the target lesion is moderately or severely calcified by visual estimate.
- Target lesion and/or target vessel proximal to the target lesion is tortuous.
- Target lesion is located within or distal to a >60 degree bend in the vessel
- Target lesion involves a bifurcation with a side branch vessel >2.0 mm in diameter.
- Target lesion is totally occluded (TIMI flow </= 1), either at baseline or predilation
- Angiographic presence of probable or definite thrombus
- Pre-treatment of the target vessel is not allowed with any device
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00371709
Principal Investigator: | Mark A Turco, MD | Washington Adventist Hospital | |
Principal Investigator: | John A Ormiston, MD | Mercy Hospital | |
Study Director: | Peter Maurer, MPH | Boston Scientific Corporation |
Responsible Party: | Boston Scientific Corporation |
ClinicalTrials.gov Identifier: | NCT00371709 |
Other Study ID Numbers: |
S2013 TAXUS ATLAS |
First Posted: | September 4, 2006 Key Record Dates |
Last Update Posted: | February 2, 2012 |
Last Verified: | February 2012 |
Coronary Artery Disease Coronary Disease Myocardial Ischemia Heart Diseases |
Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases |